Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

PBX1-SIRT1 positive feedback loop attenuates ROS-mediated HF- MSC senescence and apoptosis
Wang, Yuan , Sui, Yutong , Niu, Ye, Liu, Dan , Xu, Qi , Liu, Feilin , Zuo, Kuiyang , Liu, mingsheng, Sun, Wei , Liu, Zinan , Zou, Fei , Shi, Jiahong , Liu, Xiao mei, Liu, Jinyu , Zuo, Kuiyang , Wang, Ziyu

Mayo Clinic

No container title available | April 15, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1545647/v1 Get It

Abstract Background: Stem cell senescence and depletion are major causes of organismal aging and aging-related diseases. The NAD–SIRT1–PARP1 axis has garnered remarkable interest owing to its significant role in regulating stem cell senescence and organismal aging. Event though our recent study showes that PBX1 overexpression attenuates hair follicle-derived mesenchymal stem cell (HF-MSC) senescence and apoptosis by regulating ROS-mediated DNA damage via downregulation of PARP1 expression, suggesting PARP1 downregulation is a common manifestation of the roles of both PBX1 and SIRT1 in the attenuation of HF-MSC senescence, and implying a potential link between PBX1 and SIRT1 via PARP1. Methods: HF-MSCs overexpressing PBX1, overexpressing both PBX1 and PARP1, downregulating SIRT1, and overexpressing PBX1 and downregulating SIRT1 were generated, and biomarkers related to cell senescence, apoptosis, DNA damage, and repair were detected at the cellular and protein levels. Results: (1) PBX1 overexpression alleviated HF-MSC senescence and apoptosis accompanied by upregulation of SIRT1 expression, downregulation of PARP1 expression, and increased intracellular NAD and ATP levels. (2) SIRT1 knockdown or PARP1 overexpression enhanced cellular senescence and apoptosis, accompanied by increased ROS accumulation and DNA damage aggravation and decreased intracellular NAD and ATP levels. (3) PBX1 overexpression rescued HF-MSC senescence and apoptosis induced by SIRT1 knockdown or PARP1 overexpression. (4) Dual luciferase reporter showed PBX1 enhanced SIRT1 expression by activating SIRT1 promoter. Conclusions: Our results reveal that a positive interaction feedback loop exists between PBX1 and SIRT1, that PBX1 is the upstream of SIRT1. To the best of our knowledge we are the first to report that there is a PBX1-SIRT1-PARP1 axis and this axis plays a critical role in alleviation of HF-MSC senescence and apoptosis. The results provide a new perspective on the mechanism of stem cell senescence and age-related disease prevention and treatment.
Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial
Shanafelt, Tait D. , Wang, Victoria , Hanson, Curtis A. , Paietta, Elisabeth , O’Brien, Susan , Jelinek, Diane F., Braggio, Esteban , Leis, José F., Zhang, Cong Christine, Cashen, Amanda F. , Mato, Anthony R. , Singh, Avina K., Mullane, Michael P., Little, Richard F. , Stone, Richard M. , Litzow, Mark R. , Tallman, Martin S. , Braggio, Esteban , Barr, Paul M , Little, Richard F , Erba, Harry Paul , Litzow, Mark R. , Kay, Neil E , Shanafelt, Tait D , Barrientos, Jacqueline C. , Coutré, Steven , Barr, Paul M. , Kay, Neil E.

Mayo Clinic

Blood | April 15, 2022 | Volume: 140 | Issue: 2 | Pages: 112-120

10.1182/blood.2021014960 | PMID 35427411 Get It

Abstract Herein, we present the long-term follow-up of the randomized E1912 trial comparing the long-term efficacy of ibrutinib–rituximab (IR) therapy to fludarabine, cyclophosphamide, and rituximab (FCR) and describe the tolerability of continuous ibrutinib. The E1912 trial enrolled 529 treatment-naïve patients aged ≤70 years with chronic lymphocytic leukemia (CLL). Patients were randomly assigned (2:1 ratio) to receive IR or 6 cycles of FCR. With a median follow-up of 5.8 years, median progression-free survival (PFS) is superior for IR (hazard ratio [HR], 0.37; P < .001). IR improved PFS relative to FCR in patients with both immunoglobulin heavy chain variable region (IGHV) gene mutated CLL (HR: 0.27; P < .001) and IGHV unmutated CLL (HR: 0.27; P < .001). Among the 354 patients randomized to IR, 214 (60.5%) currently remain on ibrutinib. Among the 138 IR-treated patients who discontinued treatment, 37 (10.5% of patients who started IR) discontinued therapy due to disease progression or death, 77 (21.9% of patients who started IR) discontinued therapy for adverse events (AEs)/complications, and 24 (6.8% of patients who started IR) withdrew for other reasons. Progression was uncommon among patients able to remain on ibrutinib. The median time from ibrutinib discontinuation to disease progression or death among those who discontinued treatment for a reason other than progression was 25 months. Sustained improvement in overall survival (OS) was observed for patients in the IR arm (HR, 0.47; P = .018). In conclusion, IR therapy offers superior PFS relative to FCR in patients with IGHV mutated or unmutated CLL, as well as superior OS. Continuous ibrutinib therapy is tolerated beyond 5 years in the majority of CLL patients. This trial was registered at www.clinicaltrials.gov as #NCT02048813.
Endoscopic submucosal dissection for colorectal dysplasia in inflammatory bowel disease: a US multicenter study
Ngamruengphong, Saowanee , Aihara, Hiroyuki , Friedland, Shai , Benias, Petros C. , Draganov, Peter V. , Kumta, Nikhil A. , Borman, Zachary A. , Dixon, Rebekah E. , Marion, James F., Tomizawa, Yutaka , Mohapatra, Sonmoon , Charabaty, Aline , Lazarev, Mark , Figueroa, Esteban, Hanada, Yuri , Song, Louis M. Wong Kee , Wong Kee Song, Louis M, Nishimura, Makoto , Faleck, David M. , Yang, Dennis J. , D'Souza, Lionel S. , Jit, Simran, Parian, Alyssa M. , Wang, Andrew Y.

Mayo Clinic

Endoscopy International Open | April 14, 2022 | Volume: 10 | Issue: 04 | Pages: E354-E360

10.1055/a-1783-8756 | PMID 35433226 Get It

Abstract Background and study aims In patients with inflammatory bowel disease (IBD), endoscopically visible lesions with distinct borders can be considered for endoscopic resection. The role of endoscopic submucosal dissection (ESD) for these lesions is not well defined because of a paucity of data. We aimed to evaluate the outcomes of colorectal ESD of dysplastic lesions in patients with IBD across centers in the United States. Patients and methods This was a retrospective analysis of consecutive patients with IBD who were referred for ESD of dysplastic colorectal lesions at nine centers. The primary endpoints were the rates of en bloc resection and complete (R0) resection. The secondary endpoints were the rates of adverse events and lesion recurrence. Results A total of 45 dysplastic lesions (median size 30mm, interquartile range [IQR] 23 to 42 mm) in 41 patients were included. Submucosal fibrosis was observed in 73 %. En bloc resection was achieved in 43 of 45 lesions (96 %) and R0 resection in 34 of 45 lesions (76 %). Intraprocedural perforation occurred in one patient (2.4 %) and was treated successfully with clip placement. Delayed bleeding occurred in four patients (9.8 %). No severe intraprocedural bleeding or delayed perforation occurred. During a median follow-up of 18 months (IQR 13 to 37 months), local recurrence occurred in one case (2.6 %). Metachronous lesions were identified in 11 patients (31 %). Conclusions ESD, when performed by experts, is safe and effective for large, dysplastic colorectal lesions in patients with IBD. Despite the high prevalence of submucosal fibrosis, en bloc resection was achieved in nearly all patients with IBD undergoing ESD. Careful endoscopic surveillance is necessary to monitor for local recurrence and metachronous lesions after ESD.
Chemoenzymatic Synthesis of Homogeneous Heparan Sulfate and Chondroitin Sulfate Chimeras
Stancanelli, Eduardo , Wander, Rylee , Li, Jine , Wang, Zhangjie , Arnold, Katelyn , Su, Guowei , Kanack, Adam J. , Pham, Truong Quang , Padmanabhan, Anand , Xu, Yongmei , Kanack, Adam, Liu, Jian , Liu, Wei , Pagadala, Vijayakanth

Mayo Clinic

ACS Chemical Biology | April 14, 2022 | Volume: 17 | Issue: 5 | Pages: 1207-1214

10.1021/acschembio.2c00146 | PMID 35420777 Get It

Political Campaign Contributions of Surgeons in the United States Throughout the 2020 Election Cycle
Mehra, Mehul , Wang, Kendra, Sherman, Benjamin C. , Gopali, Rhea , Deme, Palvasha , Hoyt, David B., Barpujari, Awinita , Singh, Rohin , Reddy, Vamsi P.

Mayo Clinic

JAMA Surgery | April 13, 2022 | Volume: 157 | Issue: 6 | Pages: 515

10.1001/jamasurg.2022.0798 | PMID 35416934 Get It

Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology
Thompson, John A. , Schneider, Bryan J. , Brahmer, Julie R. , Achufusi, Amaka, Armand, Philippe , Bhatia, Shailender , Chokshi, Saurin , Davies, Marianne, Elshoury, Amro, Gesthalter, Yaron , Kaffenberger, Benjamin H. , Li, Tianhong , Marr, Alissa , McGettigan, Suzanne , Medina, Theresa , Mohindra, Nisha , Oluwole, Olalekan O. , Patel, Sandip Pravin , Patil, Pradnya D. , Reddy, Sunil , Ryder, Mabel , Shofer, Scott , Sosman, Jeffrey A. , Lyons, Megan , Dwyer, Mary A., Hang, Lisa, Oluwole, Olalekan O , Kaffenberger, B , Ryder, Mabel , Berkenstock, Meghan , Budde, Lihua E. , Hegde, Aparna , Jain, Michael D. , Lechner, Melissa G , McPherson, Jordan P. , Medina, Theresa Michelle , Olszanski, Anthony J. , Santomasso, Bianca , Wang, Yinghong , Zaha, Vlad G

Mayo Clinic

Journal of the National Comprehensive Cancer Network | April 7, 2022 | Volume: 20 | Issue: 4 | Pages: 387-405

10.6004/jnccn.2022.0020 | PMID 35390769 Get It

The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy. The NCCN Management of Immunotherapy-Related Toxicities Panel is an interdisciplinary group of representatives from NCCN Member Institutions, consisting of medical and hematologic oncologists with expertise across a wide range of disease sites, and experts from the areas of dermatology, gastroenterology, endocrinology, neurooncology, nephrology, cardio-oncology, ophthalmology, pulmonary medicine, and oncology nursing. The content featured in this issue is an excerpt of the recommendations for managing toxicities related to CAR T-cell therapies and a review of existing evidence. For the full version of the NCCN Guidelines, including recommendations for managing toxicities related to immune checkpoint inhibitors, visitNCCN.org.
Transcriptional landscape of human microglia implicates age, sex, and APOE‐related immunometabolic pathway perturbations
Patel, Tulsi , Carnwath, Troy , Wang, Xue , Allen, Mariet , Lincoln, Sarah, Lewis‐Tuffin, Laura J. , Quicksall, Zachary , Lin, Shu, Tutor‐New, Frederick Q, Ho, Charlotte C.G. , Min, Yuhao , Malphrus, Kimberly G., Nguyen, Thuy , Martin, Elizabeth, Al‐kharboosh, Rawan , Chaichana, Kaisorn L. , Wharen, Robert E. , Guerrero‐Cazares, Hugo , Quiñones‐Hinojosa, Alfredo , Ertekin‐Taner, Nilüfer , Carnwath, Troy P, Lincoln, Sarah J, Quicksall, Zachary S, Garcia, César A. , Alkharboosh, Rawan M, Chaichana, Kaisorn, Wharen, Robert, Ertekin-Taner, Nilüfer , Guerrero-Cazares, Hugo , Grewal, Sanjeet S.

Mayo Clinic

Aging Cell | April 7, 2022 | Volume: 21 | Issue: 5 | Pages: No page available

10.1111/acel.13606 | PMID 35388616 Get It

AbstractMicroglia have fundamental roles in health and disease; however, effects of age, sex, and genetic factors on human microglia have not been fully explored. We applied bulk and single‐cell approaches to comprehensively characterize human microglia transcriptomes and their associations with age, sex, and APOE. We identified a novel microglial signature, characterized its expression in bulk tissue and single‐cell microglia transcriptomes. We discovered microglial co‐expression network modules associated with age, sex, and APOE‐ε4 that are enriched for lipid and carbohydrate metabolism genes. Integrated analyses of modules with single‐cell transcriptomes revealed significant overlap between age‐associated module genes and both pro‐inflammatory and disease‐associated microglial clusters. These modules and clusters harbor known neurodegenerative disease genes including APOE, PLCG2, and BIN1. Meta‐analyses with published bulk and single‐cell microglial datasets further supported our findings. Thus, these data represent a well‐characterized human microglial transcriptome resource and highlight age, sex, and APOE‐related microglial immunometabolism perturbations with potential relevance in neurodegeneration.
Neuropilin-1 deficiency in vascular smooth muscle cells is associated with hereditary hemorrhagic telangiectasia arteriovenous malformations
Kilari, Sreenivasulu , Wang, Ying , Singh, Avishek , Graham, Rondell P. , Iyer, Vivek , Thompson, Scott M. , Torbenson, Michael , Misra, Sanjay , Misra, Sanjay , Iyer, Vivek N , Graham, Rondell P , Torbenson, Michael S , Wang, Ying , Kilari, Sreenivasulu , Mukhopadhyay, Debabrata

Mayo Clinic

JCI Insight | April 5, 2022 | Volume: 7 | Issue: 9 | Pages: No page available

10.1172/jci.insight.155565 | PMID 35380991 Get It

Patients with hereditary hemorrhagic telangiectasia (HHT) have arteriovenous malformations (AVMs) with genetic mutations involving the activin-A receptor like type 1 ( ACVRL1 or ALK1 ) and endoglin ( ENG ). Recent studies have shown that Neuropilin-1 (NRP-1) inhibits ALK1. We investigated the expression of NRP-1 in livers of patients with HHT and found that there was a significant reduction in NRP-1 in perivascular smooth muscle cells (SMCs). We used Nrp1 SM22KO mice ( Nrp1 was ablated in SMCs) and found hemorrhage, increased immune cell infiltration with a decrease in SMCs, and pericyte lining in lungs and liver in adult mice. Histologic examination revealed lung arteriovenous fistulas (AVFs) with enlarged liver vessels. Evaluation of the retina vessels at P5 from Nrp1 SM22KO mice demonstrated dilated capillaries with a reduction of pericytes. In inflow artery of surgical AVFs from the Nrp1 SM22KO versus WT mice , there was a significant decrease in Tgfb1 , Eng , and Alk1 expression and phosphorylated SMAD1/5/8 (pSMAD1/5/8), with an increase in apoptosis. TGF-β1–stimulated aortic SMCs from Nrp1 SM22KO versus WT mice have decreased pSMAD1/5/8 and increased apoptosis. Coimmunoprecipitation experiments revealed that NRP-1 interacts with ALK1 and ENG in SMCs. In summary, NRP-1 deletion in SMCs leads to reduced ALK1, ENG, and pSMAD1/5/8 signaling and reduced cell death associated with AVM formation.